Skip to content
Precision for Medicine
AdobeStock_171759632

Global Immune Monitoring Solutions

Precision provides comprehensive immune monitoring services, from the development of customized assays for early clinical studies to managing the logistical and immune monitoring testing needs of global, registrational trials. We leverage multiple technology platforms on a global scale, including proprietary innovations like Epiontis ID®.

Industry-leading array of comprehensive immune monitoring solutions

Unraveling the complexities of immunity: tailored solutions for detailed insights

  • Explore
    cytometry

    Flow Cytometry

    Standard and spectral flow cytometry, on both research-grade and CLIA-validated instruments
    Explore

    Flow Cytometry

    Standard and spectral flow cytometry, on both research-grade and CLIA-validated instruments
    Explore
  • Explore

    Epiontis ID® Epigenetic Cell Profiling

    Precision’s proprietary immune monitoring technology which delivers robust, repeatable, and cost-effective immune cell phenotyping on any sample type
    Explore

    Epiontis ID® Epigenetic Cell Profiling

    Precision’s proprietary immune monitoring technology which delivers robust, repeatable, and cost-effective immune cell phenotyping on any sample type
    Explore
  • Explore
    Cytokine

    Cytokine Profiling & Proteomics

    Customized assays to detect cytokines or proteins of interest utilizing ELISA, Luminex, MSD, SIMOA, and Western Blotting

    Explore

    Cytokine Profiling & Proteomics

    Customized assays to detect cytokines or proteins of interest utilizing ELISA, Luminex, MSD, SIMOA, and Western Blotting

    Explore
  • Explore

    ELISpot and Fluorospot

    ELISpot and FluoroSpot - including custom assays in support of gene therapy immunogenicity - from preclinical through clinical development

    Explore

    ELISpot and Fluorospot

    ELISpot and FluoroSpot - including custom assays in support of gene therapy immunogenicity - from preclinical through clinical development

    Explore
  • Explore

    Cell-Based Assays

    Developing and qualifying 2D and 3D human in vitro cell-based models using a broad range of human primary cell types, with analysis enabling a variety of endpoints
    Explore

    Cell-Based Assays

    Developing and qualifying 2D and 3D human in vitro cell-based models using a broad range of human primary cell types, with analysis enabling a variety of endpoints
    Explore
  • Explore
    shutterstock_1890095569
    companion-diagnostic

    Gene Expression Profiling of Biopsies

    Understand target expression, adaptive and innate immune responses at the gene expression level. Technologies we use for gene expression profiling include NanoString, Illumina RNA-seq, ddPCR, and qPCR.

    Explore
    companion-diagnostic

    Gene Expression Profiling of Biopsies

    Understand target expression, adaptive and innate immune responses at the gene expression level. Technologies we use for gene expression profiling include NanoString, Illumina RNA-seq, ddPCR, and qPCR.

    Explore

Efficient sample management logistics enable global immune monitoring services

Precision’s immune monitoring services are strengthened by a global logistics network, designed to safeguard sample integrity and maximize data reliability.

Clinical Reach

Global clinical sample and PBMC processing

  • Global PBMC processing in 24-hours or less
  • Regular competency assessment and monitoring to ensure site-to-site and lab-to-lab data comparability
  • Long- and short-term storage at optimal temperatures

Clinical sample logistics and biostorage

We have a 100,000 sq. ft. biorepository, which includes our 140,000 sq. ft. campus in Frederick, Maryland, and our global logistics and biobanking facilities in Berlin, Germany. This extensive network was the first to receive CAP certification. Currently, we are responsible for the storage of >20 million biospecimens under controlled conditions. We can accommodate any type of fluid or solid biological specimen at controlled ambient temperatures, +4℃, -20℃, -80℃, or in liquid nitrogen vapor.

The biorepository includes numerous security and safety features:

  • Redundant back-up systems, dedicated back-up units
  • Around-the-clock automated temperature monitoring
  • In-house HVAC technicians, specializing in cascade refrigeration

Unlocking potential: flow cytometry for breakthrough research

Precision for Medicine offers a suite of flow cytometry services tailored to the intricate demands of modern scientific research and therapeutic development

Brochure

High-Content Flow Cytometry

Download Brochure
High-Content Flow Cytometry

Epiontis ID® - Optimized Immune Profiling

Within our suite of immune monitoring services, Epiontis ID® proprietary technology stands out by offering an epigenetic approach to cell profiling. See how it works.

Explore

Related resources

Blog - Ut libero urna, finibus sed tortor nec, fringilla blandit est

Nullam fermentum, massa vel lacinia pellentesque, nulla erat condimentum ipsum, ac blandit sapien neque sed sem. Quisque bibendum semper erat, nec luctus ligula.

Read: Radiopharmaceutical Clinical Trials: What Sponsors Need to Know About Selecting a CRO Radiopharmaceutical Clinical Trials: What Sponsors Need to Know About Selecting a CRO

Clinical Trials - Oncology

Radiopharmaceutical Clinical Trials: What Sponsors Need to Know About Selecting a CRO

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778843, hs_child_table_id=0, hs_updated_at=1774960706353, hs_published_at=1774960708819, description=Robert Bauer is an Executive Director of Operational Strategy at Precision with over 20 years of clinical trial operations experience from both the sponsor and CRO perspectives. He has led teams in the conduct of trials from Phase I through IV and has experience across a wide variety of trial designs. Bob has experience across many therapeutic areas some of which include rare diseases, oncology, depression, schizophrenia, and substance use disorders., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Robert%20Bauer%20Square.webp',altText='Robert Bauer Square',fileId=165892429961}, linkedin=https://www.linkedin.com/in/robert-bauer-a78b704b, hs_name=, hs_path=, lastname=Bauer, hs_initial_published_at=1774887084379, hs_created_at=1709645745074, hs_is_edited=false, hs_deleted_at=0, name=Robert, position=Vice President, Operational Strategy, job=, slug=robert-bauer, email=, hs_updated_by_user_id=65160865}, second={hs_id=185416008260, hs_child_table_id=0, hs_updated_at=1754641208207, hs_published_at=1774960708819, description=Sarika is a Senior Clinical Trial Manager with 14+ years of experience in clinical research, specializing in oncology, rare diseases, and cardiology. With a robust focus on Phase I-IV clinical trials, she has successfully led projects from start-up to close-out and has experience in cohort management and solid tumor studies. She is a strong advocate for cross-functional teamwork, streamlining processes, and optimizing project efficiency., avatar=Image{width=287,height=287,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/Sarika-David-Armogan-1-1.png',altText='Sarika-David-Armogan-1-1',fileId=194123711873}, lastname=David-Armogan, hs_initial_published_at=1737992355064, hs_created_by_user_id=26433386, hs_created_at=1737992180108, hs_is_edited=false, hs_deleted_at=0, name=Sarika, slug=sarika-david-armogan, hs_updated_by_user_id=65160865}, third={}})
  • Robert B. avatar

    Robert B.

  • Sarika D. avatar

    Sarika D.

Discover
Read: Cancer Is the Enemy: How Phase I Oncology Teams Accelerate Drug Development Cancer Is the Enemy: How Phase I Oncology Teams Accelerate Drug Development

Clinical Trials - Oncology

Cancer Is the Enemy: How Phase I Oncology Teams Accelerate Drug Development

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778858, hs_child_table_id=0, hs_updated_at=1754641583843, hs_published_at=1774960708819, description=Rob Maiale is a marketing strategist and creative technologist with 17 years of experience turning complex ideas into growth. He currently leads content strategy, where he transforms insights from Precision experts into market-shaping narratives that drive the advancement of next-generation therapies.  Rob’s career spans journalism, advertising, and brand storytelling, with a through-line of making the meaningful memorable. His work blends creative strategy with emerging AI tools to help Precision stay ahead of the curve—and above the noise., avatar=Image{width=287,height=287,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/rob.png',altText='rob',fileId=194099000843}, linkedin=https://www.linkedin.com/in/rob-maiale/, hs_name=, hs_path=, lastname=Maiale, hs_initial_published_at=1774887084379, hs_created_at=1709645745089, hs_is_edited=false, hs_deleted_at=0, name=Rob, position=Associate Director, Digital Content & Inbound Marketing, job=, slug=rob-maiale, email=, hs_updated_by_user_id=65160865}, second={}, third={}})
  • Rob Maiale avatar

    Rob Maiale

Discover
Read: Expanding Clinical Trial Execution in Greater China: Beijing, Shanghai, Hong Kong & Taiwan Expanding Clinical Trial Execution in Greater China: Beijing, Shanghai, Hong Kong & Taiwan

Clinical Trials

Expanding Clinical Trial Execution in Greater China: Beijing, Shanghai, Hong Kong & Taiwan

|
    has third author: false, (SizeLimitingPyMap: {main={hs_id=199521241215, hs_child_table_id=0, hs_updated_at=1774887081250, hs_published_at=1774960708819, description=An industry veteran with nearly three decades of experience in the clinical research industry and deep expertise in clinical operations and strategic leadership across both pharmaceutical and CRO environments. Held pivotal roles as Head of Clinical Operations for Greater China at Boehringer Ingelheim, leading trials in oncology, respiratory, stroke, and cardio-metabolic diseases and CEO of George Clinical, a global CRO with strong scientific capabilities in renal and oncology therapeutic areas. At Precision for Medicine, a leader for business strategy across the Asia Pacific region. Focused on driving regional growth, building strategic partnerships, and supporting excellence in portfolio delivery and client satisfaction. An acknowledged driver of precision-driven solutions that improve patient outcomes., avatar=Image{width=276,height=290,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/James%20Cheong.png',altText='James Cheong',fileId=199519079710}, linkedin=https://www.linkedin.com/in/james-cheong-36a543a/, lastname=Cheong, hs_initial_published_at=1762885727645, hs_created_by_user_id=78347666, hs_created_at=1762885637470, hs_is_edited=false, hs_deleted_at=0, name=James, job=Senior Vice President, Asia Pacific, Clinical Solutions​, slug=james-cheong, hs_updated_by_user_id=65160865}, second={hs_id=199519203221, hs_child_table_id=0, hs_updated_at=1770145994248, hs_published_at=1774960708819, description=Highly accomplished global clinical operations executive with nearly three decades of experience providing strategic leadership, regional expansion, and operational excellence across Asia Pacific. Brings deep expertise across clinical development, project and portfolio operations, biometrics, regulatory affairs, safety and pharmacovigilance, quality management, and financial governance. Proven builder and scaler of high‑performing teams and start‑up operations in both regional and global environments. Recognized industry leader who actively contributes to advancing clinical research standards through advisory and governance roles across Asia., avatar=Image{width=276,height=290,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Jing%20Ping%20Yeo.png',altText='Jing Ping Yeo',fileId=199530854290}, linkedin=https://www.linkedin.com/in/jing-ping-yeo/, lastname=Yeo, PhD , hs_initial_published_at=1762893310168, hs_created_by_user_id=78347666, hs_created_at=1762893091367, hs_is_edited=false, hs_deleted_at=0, name=Jing Ping, job=Vice President, Clinical Operations, Head of Asia Pacific​, slug=JingPing-Yeo, hs_updated_by_user_id=65160865}, third={hs_id=199528025104, hs_child_table_id=0, hs_updated_at=1774885968488, hs_published_at=1774960708819, description=With 20+ years of experience in the clinical trial industry, he has led project management, clinical operations, and business development teams. Prior to joining Precision, he served as the General Manager of Emerald (formerly George Clinical) China, and held project management and business development leadership roles at ICON, WuXi CDS, IQVIA, and KUNTUO. He has successfully led teams to complete more than 120 Phase I–IV clinical trials, many of which were MRCT studies across Asia‑Pacific, Australia, and the United States. He holds a Master’s degree in Urology from Peking University First Hospital., avatar=Image{width=276,height=290,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Zhenfei%20Yin.png',altText='Zhenfei Yin',fileId=199530854553}, lastname=Yin, hs_initial_published_at=1762893310168, hs_created_by_user_id=78347666, hs_created_at=1762893190542, hs_is_edited=false, hs_deleted_at=0, name=Zhenfei, job=China Country Head, Senior Director, Project Management​, slug=Zhenfei Yin, hs_updated_by_user_id=65160865}})
  • James C. avatar Jing Ping Y. avatar Zhenfei Y. avatar
  • James C.

    Jing Ping Y.

    Zhenfei Y.

Discover